Investigation about insulin doses and blood glucose control in changes from insulin glargine U-100 to insulin glargine U-300 for patients with diabetes.

Investigation about insulin doses and blood glucose control in changes from insulin glargine U-100 to insulin glargine U-300 for patients with diabetes. - Investigation about insulin doses and blood glucose control in changes from insulin glargine U-100 to insulin glargine U-300 for patients with diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027364

Enrollment

150

Registered

2017-05-17

Start date

2016-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

To switch from insulin glargine U-100 to insulin glargin U-300.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patient who gives a written informed. 2)The patient who is receiving treatment with insulin glargine u-100 by once or twice a day. 3)Male and Female,the age 20 years old or older.

Exclusion criteria

Exclusion criteria: 1)The pregnant woman and/or a woman under breast-feeding. 2)The patient with intolerance of medical reasons by doctor. 3)The patients with hypersensitivity for insulin glargin U-300. 4)The patients with serious complications and considered inappropriate to participate in this study by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
satisfaction of the change to insulin glargine U-300 by using Questionnaire, insulin dose, bodyweight, BMI, glucose, a ratio of basal insulin (basal-bolou therapy), hypoglycemia (hypoglycemic symptom or glucose level at self monitering glucose)	—

Countries

Japan

Contacts

Public ContactToshie Iijima

Dokkyo Medical University Hospital Department of Endocrinology and Metabolism

toshie@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026